Sign Up Today and Learn More About Synthego Stock
Invest in or calculate the value of your shares in Synthego or other pre-IPO companies through EquityZen's platform.
Synthego Stock (SYNH)
Genome Engineering Solutions
Synthego is a provider of genome engineering solutions.The company's flagship product, CRISPRevolution, is a portfolio of synthetic RNA designed for CRISPR genome editing and research. CRISPR genome engineering technology enables scientists to easily and precisely edit the DNA of any genome. Select applications of gene editing include: pathway analysis, stem cells, and diagnostics. The company also offers two products: CRISPR-edited iPS cells and Engineered Cells. See here for more detailed information on Synthego's products. Synthego aims to bring precision and automation to genome engineering, enabling rapid and costeffective research with consistent results for every scientist. The company is headquartered in Silicon Valley, California and was founded in July 2012.
About Synthego Stock
Founded
2012
Headquarters
Redwood City, CA, US
Total Funding
415M
Industries
Manufacturing, Software, Data and Analytics
Synthego is a provider of genome engineering solutions. The company offers CRISPR kits, such as the CRISPR evolution, a portfolio of synthetic RNA designed for CRISPR genome editing and research. Synthego claims that its CRISPR genome engineering technology enables scientists to easily and precisely edit the DNA of any genome. Select applications of gene editing include pathway analysis, stem cells, and diagnostics. The company also offers two products: CRISPR-edited iPS cells and Engineered Cells.
The company is headquartered in Redwood City, CA, and was founded in July 2012. Notable investors include Founders Fund, 8VC, and Menlo Ventures.
Synthego Press Mentions
Stay in the know about the latest news on Synthego
Synthego Gains Approval to Proceed with Sale to Perceptive Advisors; Transaction Set to Close in July
prnewswire • Jun 27, 2025
Synthego Gains Approval to Proceed with Sale to Perceptive Advisors; Transaction Set to Close in July
biospace • Jun 27, 2025
Synthego Gains Approval to Proceed with Sale to Perceptive Advisors; Transaction Set to Close in July
morningstar • Jun 27, 2025
Synthego Prevails In Patent Appeal Confirming Agilent CRISPR Patents Are Invalid
prnewswire • Jun 12, 2025
Synthego Prevails In Patent Appeal Confirming Agilent CRISPR Patents Are Invalid
biospace • Jun 12, 2025
Investors in Synthego
Discover investors in Synthego stock and explore their portfolio companies
Synthego Management
Leadership team at Synthego
Chief Executive Officer
Paul Dabrowski
Chief Financial Officer
Avi Raval
Join now and verify your accreditation status to gain access to:
- Synthego Current Valuation
- Synthego Stock Price
- Synthego Management
- Available deals in Synthego and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Synthego Cap Table and Funding History by Share Class and Liquidity Preferences
- Synthego Revenue and Financials
- Synthego Highlights
- Synthego Business Model
- Synthego Risk Factors
- Synthego Research Report from SACRA Research
Synthego Key Facts
• Flexible production capabilities outlined by Synthego aim to enable the company to scale operations efficiently in response to market dynamics and customer needs, supporting revenue growth and operational resilience.
• Continual advancements in CRISPR technology, such as next-generation nucleases and delivery methods, demonstrate Synthego's commitment to enhancing editing capabilities and addressing challenges in gene therapy, agriculture, and industrial biotechnology.
• Positive regulatory developments and increasing acceptance of genome editing technologies, such as CRISPR, for clinical applications pave the way for future commercialization opportunities and revenue diversification.
• Advances in alternative genome editing technologies or improvements in existing CRISPR platforms by competitors could erode Synthego's market position and reduce its differentiation in the rapidly evolving biotech industry.
• Regulatory uncertainty or stringent regulatory requirements in key markets (such as FDA approvals for clinical trials) may hinder Synthego's ability to commercialize CRISPR-based therapies or expand into new applications.
• Reductions in research budgets, healthcare reforms impacting biopharmaceutical investments, or delays in clinical trials due to external economic factors could adversely affect Synthego's sales growth and financial performance.
Trading Synthego Stock
How to invest in Synthego stock?
Accredited investors can buy pre-IPO stock in companies like Synthego through EquityZen funds. These investments are made available by existing Synthego shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Synthego stock?
Shareholders can sell their Synthego stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
